Patent ID: 11887713
Assignee: ELUCID BIOIMAGING INC.
Field: Medical technology (Instruments)
Classification: CPC G | IPC G

Claim 14:
15. A method of identifying one or more contraindications associated with an anti-diabetic therapy for a patient diagnosed with atherosclerotic cardiovascular disease, the method comprising:
receiving a first input of non-invasively obtained imaging data related to a plaque from a set of test subjects;
receiving a second input of molecular expression data from the set of test subjects;
creating a training set comprising the first input and the second input;
training a neural network using the training set, the neural network configured to predict molecule levels based on the non-invasively obtained imaging data from the set of test subjects;
receiving non-invasively obtained imaging data related to a plaque from the patient;
generating virtual ′omics data that include predicted molecule levels of the patient, by applying the neural network to the non-invasively obtained imaging data from the patient;
providing the virtual ′omics data to a systems biology model of atherosclerotic cardiovascular disease to generate a patient-specific systems biology model, wherein
(i) the systems biology model represents a plurality of pathways associated with atherosclerotic cardiovascular disease,
(ii) each pathway in the plurality of pathways corresponds to one or more of MTOR, NFκβ1, ICAM1, or VCAM1,
(iii) the systems biology model includes a disease-associated molecule level for each molecule in the systems biology model, and
(iv) the patient-specific systems biology model includes predicted molecule levels that are updated from the disease-associated molecule level;

updating the patient-specific systems biology model with information relating to an effect on glucose levels by an anti-diabetic agent based on a known mechanism of action of the anti-diabetic agent;
simulating a therapeutic response by the patient to the anti-diabetic agent in the updated patient-specific systems biology model to obtain a simulated therapeutic effect, wherein the simulated therapeutic effect is based on change in the predicted molecule levels in the updated patient-specific systems biology model with and without the anti-diabetic agent; and
identifying one or more contraindications associated with the anti-diabetic agent based on change in the predicted molecule levels in the patient-specific systems biology model with and without the anti-diabetic agent.